Regeneron R1979-ONC-1625

An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 X Anti-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Study Link

Ascentage APG-2575CU101

A Phase Ib/II Study of APG-2575 as a Single Agent or in Combination with Other Therapeutic Agents in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (SACRED)
Study Link

Antengene ATG-037-001

A Phase I/Ib, Multi-centre, Open-label, and Dose-finding Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy with Pembrolizumab in Patients with Locally Advanced or Metastatic Solid Tumours
Study Link

Ascendis ASND0029

TransCon IL-2 β/γ Alone or in Combination with Pembrolizumab or Standard of Care Chemotherapy in Participants Aged 18 Years or Older with Locally Advanced or Metastatic Solid Tumor Malignancies
Study Link

Atridia SHR-A1904-I-104

An Open-label, Single-arm, Multi-center Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SHRA1904 in Subjects with Advanced Solid Tumours Expressing Claudin 18.2
Study Link

Hanmi HM-EZHI-101

A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study of HM97662 as a Single Agent in Patients with Advanced or Metastatic Solid Tumors
Study Link

Iksuda IKS014-01

A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants with Advanced HER2+ Solid Tumors
Study Link

Eli Lilly LOXO-RAS-20001

A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors
Study Link

Stingray SR-8541A-001

Phase 1, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study of SR-8541A (ENPP1 inhibitor) Administered Orally as Monotherapy in Subjects with Advanced/Metastatic Solid Tumors
Study Link

Aulos CP-AU-007-01

A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients with Unresectable Locally Advanced or Metastatic Cancer
Study Link

Seagen SGNDV-004

A Phase 1b/2 Open-Label Study of Disitamab Vedotin Monotherapy or in Combination with Other Anticancer Therapies in Solid Tumors
Study Link

Seagen SGNDV-005

Phase 2 Basket Study of Disitamab Vedotin (ADC composed of the humanized anti-HER2 monoclonal antibody) in Adult Subjects with Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors that Express HER2
Study Link

Dragonfly DF6215-001

A Phase 1/1b, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 (modified monovalent human interleukin-2 (IL-2)-Fc C-terminus fusion protein) in Patients with Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors
Study Link

Eikon EIK1003-001

A first-in-human, Phase 1/2, open-label, multi-center, dose-escalation, dose-optimization, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PARP1 selective inhibitor, IMP1734, in patients with advanced solid tumors
Study Link

Daiichi Sankyo DS1062-A-U303

A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)
Study Link

Daiichi Sankyo DS1062-A-U304

A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (Tropion-Lung08) (Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)
Study Link

Hummingbird CRUKD/22/002

A Phase 1b Study to Evaluate HMBD-001 in Combination with Docetaxel with or without Cetuximab in Participants with Advanced Squamous Non-Small Cell Lung Cancers
Study Link

TheRas / BridgeBio TBBO8520-101

A Phase 1a/1b Open-Label Study of BBO-8520 Monotherapy and BBO-8520 in Combination with Pembrolizumab in Subjects with Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - the ONKORAS-101 Study
Study Link

BioNTech BNT327-01

A Phase II, Multi-site, Open-label, Parallel Group Trial of BNT327 in Combination With Chemotherapy for Participants With Untreated Extensive-stage Small-cell Lung Cancer and Participants With Previously Treated Small-cell Lung Cancer
Study Link

BioNTech BNT327-02

A Phase II, multi-site, randomized, open-label clinical trial to evaluate the safety, efficacy, and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer
Study Link

Seagen RC48-G001

A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) in Subjects with HER2-Expressing Locally Advanced Unresectable or Metastatic Urothelial Carcinoma
Study Link

Seagen SGNDV-001

An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and Greater)
Study Link

Ractigen RAG-01-01

A phase Ⅰ, open-label, multi-center study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of RAG-01 in patients with non-muscle-invasive bladder cancer (NMIBC) who have failed Bacillus Calmette Guérin (BCG) therapy
Study Link